07/02/25 - General information
The research center will conduct proof-of-concept studies for the potential treatments developed by the company, which specializes in drug research for such pathologies.
The Hospital del Mar Research Institute and the company Bionure have signed an agreement to establish a strategic collaboration between the two institutions. The objective is the development of new RNA-based therapies for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS).
The research center will be responsible for conducting proof-of-concept studies for potential medications, both in patient cells and in animal models, which is a necessary step before starting clinical trials in humans. RNA therapies for these types of pathologies are a promising tool not only to slow disease progression but also to potentially repair neuronal damage in neurodegenerative diseases with a genetic component.
Dr. Pablo Villoslada, director of the Neuroscience Research Program at the Hospital del Mar Research Institute, stated that "our expertise in neuroscience, combined with Bionure's RNA technology, positions us at the forefront of translational research in central nervous system diseases." In this regard, Carmen Sanfrancisco, CEO of Bionure, added that "this collaboration marks a turning point in the treatment of neurodegenerative diseases," pointing out that "RNA therapies represent the future of personalized medicine in these complex conditions."
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
